Triastek closes strategic funding round for oral peptide pipeline and Shanghai R&D center
Application
Originally reported by 投资界 (PEdaily)
Triastek (Nanjing) Pharmaceutical Technology Co., Ltd., the Chinese 3D printed drug developer, announced a new strategic funding round on July 13, 2026. Investors include Shanghai Minhang Financial Investment Development Co., Ltd., Shanghai Lingang Digital Core Private Fund Management Co., Ltd., and Hangzhou Industrial Investment Group Co., Ltd. The company will use the capital to build its Shanghai International R&D and Production Center, advance clinical trials for its oral peptide pipeline, and expand international collaboration. Triastek’s lead product, T25 (octreotide acetate tablet), has received IND clearance from both the U.S. FDA and China's NMPA for treating acromegaly.
This round marks a significant step for Triastek as it shifts strategic focus toward oral biologics delivery, a high-value frontier where 3D printing can solve longstanding bioavailability challenges. Triastek’s proprietary MED (Melt Extrusion Deposition) and MED&SSE (semi-solid extrusion) platforms enable precise microstructured oral dosage forms that protect peptide stability and target drug release to the optimal gastrointestinal absorption window. The company is one of the few globally to combine 3D printing with pharmaceutical-grade continuous manufacturing, positioning it against Aprecia Pharmaceuticals (ZipDose platform) and Merck KGaA’s internal programs, but with a stronger emphasis on oral macromolecules. The Shanghai center will leverage the city’s multinational pharma talent pool and regulatory proximity, accelerating both clinical timelines and out-licensing deals.
For the AM industry, Triastek remains the most advanced commercial application of pharmaceutical 3D printing, but the path to revenue requires navigating clinical trial outcomes and manufacturing scale-up. The company must now demonstrate that its T25 program can deliver statistically significant bioavailability improvements in Phase II/III trials, and that its continuous production line can meet GMP standards at commercial volumes. Investors and partners should watch for clinical data readouts and whether the Shanghai center attracts co-development agreements with major pharma companies seeking oral alternatives to injectable biologics.
Topics